Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Norwegian Cruise Line Holdings Ltd (NCLH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Norwegian Cruise Line Holdings Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $288.03 (market cap $39.89B), while Norwegian Cruise Line Holdings Ltd trades at $19.92 (market cap $9.00B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 4.4× Norwegian Cruise Line Holdings Ltd's market cap, and Norwegian Cruise Line Holdings Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | NCLH | |
|---|---|---|
Market Cap | $39.89B | $9.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $26.94 |
52-Week Low | $278.09 | $14.79 |
Enterprise Value | $38.15B | $23.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Norwegian Cruise Line Holdings (NCLH) trades at $19.61, down 0.76% on the day, with technical indicators showing a neutral to bearish bias amid recent volatility. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.23 surpassing expectations of $0.15, while revenue reached $9.83 billion in 2025. Analyst sentiment remains largely positive with a consensus price target of $22.06, though high debt levels and macroeconomic sensitivities present ongoing risks.
NCLH offers potential upside based on earnings momentum and favorable valuation multiples, but investors face headwinds from elevated leverage and industry-specific volatility. The stock's near-term direction hinges on Q2 2026 earnings delivery and sustained travel demand amid fluctuating fuel costs and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Norwegian Cruise Line Holdings Ltd
Norwegian Cruise Line is the world's third-largest cruise company by berths (at more than 62,000), operating 29 ships across three brands (Norwegian, Oceania, and Regent Seven Seas), offering both freestyle and luxury cruising. The company has redeployed its entire fleet as of May 2022. With eight passenger vessels on order among its brands through 2027 (representing 20,000 incremental berths), Norwegian is increasing capacity faster than its peers, expanding its brand globally. Norwegian sailed to around 500 global destinations before the pandemic.
Read more on NCLH →
